BNTC
Benitec Biopharma Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.70
P/S
518.80
EV/EBITDA
-1.96
DCF Value
$2.67
FCF Yield
-6.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-11.9%
Operating Margin
-9090.6%
Net Margin
-8327.9%
ROE
-38.9%
ROA
-24.3%
ROIC
-26.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-11.8M | $-0.26 |
| Q1 2026 | $0.00 | $-9.0M | $-0.22 |
| Q4 2025 | $556.0K | $-16.1M | $-0.39 |
| FY 2025 | $0.00 | $-37.9M | $-1.05 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.12
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.